Cabaletta Bio Inc. CABA
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Cabaletta Bio Inc. is a clinical-stage biotechnology company specializing in engineered T cell therapies for B cell–mediated autoimmune diseases. The company focuses on leveraging its proprietary CABA platform, which includes two main approaches: CARTA, or chimeric antigen receptor T cells for autoimmunity, and CAART, …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees156
TickerCABA
Statistics
Market Cap$315.0M
Revenue (TTM)$0
Net Income-$167.9M
Net Margin—
EPS$-2.10
P/E-1.44
P/S—
P/B3.24
EV/EBITDA-2.28
ROE-156.0%
Dividend Yield—
Price$2.83
Data: Twelve Data · Revenue = mcap / P/S